The global Ulcerative Colitis (UC) drug market size was USD 7.80 Billion in 2021 and is expected to register a revenue CAGR of 5.1% during the forecast period. Increasing prevalence rate of ulcerative colitis and similar Inflammatory Bowel Diseases (IBD), development of biosimilars, and rising demand for application of IBD treatment in developing countries are some of the key factors driving market revenue growth.
Ulcerative colitis drugs are witnessing a rise in demand owing to focus on diagnosis and treatment to minimize and control signs and symptoms of the disease. At present, there is no permanent cure for ulcerative colitis and exact cause for occurrence of this condition remains unknown, but there are several types of drugs, which are effective for treatment of the symptoms. This type of medication/remedy prescribed to a patient largely depends on the cause and severity of disease. In addition, medications given to patients affected by this condition usually focus on reducing swelling and inflammation, as well as maintaining a proper diet, which helps in alleviating many symptoms. According to research, in 2020, there were around 2.5 million cases of inflammatory bowel disease in the U.S. and it is expected to affect around 3.5 million people in the U.S. by 2030. Incidence and prevalence of inflammatory bowel disorders (IBD), which affected 0.2% of Europe’s population in 2020, appear to be rising in Europe as well.
Request a Sample@ https://qyresearchmedical.com/sample/118980
Players in the market are emphasizing on R&D activities, which, in turn, is driving market revenue growth. For example, on July 2022, RINVOQ (upadacitinib) received approval from the European Commission for treatment of individuals with slightly to highly active ulcerative colitis who haven’t reacted effectively, have stopped responding, or have grown intolerable to either standard therapy or a biologic medication. According to reports, during U-ACHIEVE and U-ACCOMPLISH induction studies, 73% and 74% of patients treated with RINVOQ 45 mg showed a clinical response (per Adapted Mayo Score) at week 8 as opposed to 27% and 25% of patients receiving a placebo, respectively.
Market Dynamics:
Driver: Increase in prevalence rate of ulcerative colitis and similar inflammatory bowel diseases
The global ulcerative colitis drug market is being driven by an increase in incidence of ulcerative colitis and inflammatory bowel disease (IBD) worldwide. IBD, a set of inflammatory gastrointestinal disorders, predominantly includes Crohn’s disease and ulcerative colitis. In affluent countries, substantial frequency and incidence rates of these illnesses have been noted. In addition, the market is expanding as a result of medications’ approval. For instance, in November 2021, the European Commission granted Bristol Myers Squibb permission to market Zeposia (ozanimod) for treatment of adults with moderately to severely active Ulcerative Colitis (UC) who have experienced an insufficient response, lost response, or are intolerable to either conventional therapy or a biologic agent.
Restraint: Strict government restrictions governing medicine approval
In an attempt to protect the public from negative drug-related side effects, majority of governments around the world impose regulations on pharmaceutical companies. These regulations frequently make it more difficult to release new IBD-related medications in the market. In many developed countries, new medications are put through extensive safety and effectiveness testing in an effort to reduce side effects. Worldwide drug approval regulations that are too strict keep costs high and discourage competition. Nearly USD 3 billion is spent on the development of each new drug and this cost is rising quickly. Consequently, producers will increase prices and reduce innovation. People all over the world could have regular access to numerous life-saving medications with a streamlined regulatory process. Furthermore, strict government restrictions and regulations governing medicine approval are expected to restrain revenue growth of the market.
Some Key Takeaways:
Drug Type Outlook:
Based on drug type, the global ulcerative colitis drug market is segmented into biologics, corticosteroids, immunomodulators, 5-aminosalicylic acid, immunosuppressants, biosimilars, and others. The biologics segment accounted for largest revenue share in 2021 owing to its effectiveness in working in a selective manner, rather than affecting the whole body, which results in reducing medication-related side effects and elevated preference among care providers and care users.
The immunomodulators segment is expected to register fastest revenue growth rate during the forecast period. This group of drugs inhibits or regulates body’s immunological response, preventing it from perpetuating inflammation. Immunomodulators are typically used when corticosteroids and aminosalicylates have failed to act, or have only partially worked, which may take many months to start working. These drugs may help persons who haven’t responded to previous drugs used for this purpose to maintain remission and reduce or eliminate the requirement for corticosteroids. Some immunomodulators are employed to improve efficacy of other drugs including biologics. Some of the drug compounds might include azathioprine, 6-mercaptopurine, cyclosporine, and others.
Route of Administration Outlook:
Based on route of administration, the global ulcerative colitis drug market is segmented into oral and injectable. The injectable segment accounted for a significant revenue share in 2021. This is attributed to the fact that major drugs for treating this condition, such as biologics, are administered in this form. Furthermore, when medications are administered in the form of injectable, it works in a selective and precise manner, which results in their high presence among care providers.
The oral segment is expected to register fastest revenue growth rate during the forecast period because of the development of new oral drugs to treat ulcerative colitis. Pharmaceutical and medical device industries have expanded their R&D efforts as a result of a rise in demand for pharmaceuticals used in treatment, which has fueled market expansion. Furthermore, new drugs are also being developed with increase in number of market players in the medical device industry and rise in instances of ulcerative colitis.
Distribution Channel Outlook:
Based on distribution channels, the global ulcerative colitis drug market is segmented into hospital pharmacies, online pharmacies, and retail pharmacies. The hospitals and clinics segment accounted for largest revenue share in 2021 owing to a number of factors, including availability of highly qualified healthcare professionals, increased buying power, well-equipped diagnostic rooms, and enhanced health coverage for hospital-based healthcare services from several individual and group insurance policies, among others. In addition, rising incidence rate of this condition, increase in number of in-patients and out-patients, and rise in number of hospitalizations linked to the disease all other factors expected to drive revenue growth of this segment.
The online pharmacy segment is expected to register a significant revenue CAGR over the forecast period. Growth of online medicine shops and rising trend of online purchases of medicines owing to benefits, such as comfort, convenience, and various offers in these shops, contribute to the growth rate witnessed by this segment. After pandemic, online purchasing has seen one of the fastest growth rates and with the arrival of 5G network, it is expected to grow even further.
Application Outlook
Based on application the global ulcerative colitis drugs market is segmented into proctosigmoiditis, ulcerative proctitis, pancolitis, left-sided colitis, and acute severe ulcerative colitis. The ulcerative proctitis segment accounted for largest revenue share in 2021. Diseases, such as ulcerative colitis and Crohn’s disease, are associated with autoimmune proctitis. If there is solely rectum-specific inflammation, it may fluctuate or ascend into large intestine. In addition, high prevalence of ailment leads to strong demand for UC medications in the market. Doctors will treat radiation proctopathy depending on how severe the symptoms are and if the symptoms are modest, doctors frequently suggest medications to aid with discomfort relief and rectum lining healing.
The pancolitis segment is expected to register a steady revenue CAGR during the forecast period. Similar to other inflammatory bowel diseases, pancolitis can be caused by genes. One theory is that genes are thought to cause Crohn’s disease. Another type of IBD may also cause UC. Treatments for pancolitis of ulcerative colitis depend on how severe ulcers in the colon are. Treatment may also vary depending on underlying conditions that caused pancolitis or if untreated pancolitis has caused more severe conditions. Most common treatment for pancolitis and other forms of UC are anti-inflammatory drugs, which helps to treat inflammation in colon. These include medications such as oral 5-aminosalicylates (5-ASAs) and corticosteroids. Improvements in the treatment of IBD-related pancolitis, which are driving revenue growth of this segment.
Regional Outlook:
Based on regional analysis, the North America market is expected to register largest revenue share over the forecast period owing to advanced healthcare system in the U.S., rise in knowledge and awareness amongst people about diseases, and technological advancement in this region. In addition, the U.S. and Canada’s high prevalence and rising incidence of Crohn’s disease and ulcerative colitis, as well as region’s established healthcare system and high risk of lifestyle-related variables are other factors driving revenue growth in this region. Moreover, the worldwide IBD (ulcerative colitis and Crohn’s disease) therapy market in this region is expected to be driven by strong product pipelines of leading competitors. The market expansion is also being aided by market’s participants’ expanding research efforts. For instance, Eli Lilly and Company started a phase II research study in Canada in March 2021 to examine the effectiveness and safety of LY3471851 in adult patients with active Ulcerative Colitis (UC). Furthermore, investigation should be finished in October 2024, thus, aforementioned factors are expected to fuel market expansion in this area during the forecast period.
The Europe market is expected to account for a significant revenue share during the forecasted period. The Europe market is expanding faster compared to previous years, owing to increase in number of patients visiting hospitals with ulcerative colitis. In addition, demand for products in this market is being fueled by efforts to raise awareness among people so that they can lessen the severity of disease when it is discovered in its early stages. Moreover, more well-equipped medical facilities in both developed and developing countries and popularity of high-quality medical operations at any cost are driving demand for the European market. In 2021, Jyseleca, an oral, once-daily JAK1 preferential inhibitor, has been given additional approval by the European Commission for treatment of adult patients with moderately to severely active UC who have received insufficient treatment, lost response to treatment, or were intolerant to either conventional therapy or a biologic agent.
The Asia Pacific market is expected to register fastest revenue CAGR over the forecast period. This is due to changing lifestyle that triggers number of patients affected by this condition along with expansion of the healthcare sector and rising product approvals. The ulcerative colitis drug market is growing owing to large number population in this region. With India, having over 800,000 pharmacies, retail pharmacy is one of the largest in country. The market is becoming increasingly active in product development in other countries. Tofacitinib’s efficacy, safety, and Pharmacokinetics (PK) in young patients with moderately to severely active UC are being studied in phase III clinical research that was initiated by Pfizer, Inc. in June 2022. This experiment is expected to be finished in 2028. Takeda pharmaceuticals business launched a phase III research trial in Japan in June 2022, to assess effectiveness and safety of Intravenous Vedolizumab (IV), in Japanese patients with moderate to severe Ulcerative Colitis.
Competitive Landscape:
Competitive landscape of the global ulcerative colitis drug market is moderately consolidated with few major companies operating on global and regional levels. Major companies are engaged in product development and strategic alliances to expand their respective product portfolios and gain a robust footprint in the global market. Some major companies in the market report include Johnson & Johnson Services, Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, Pfizer Inc., Bristol-Myers Squibb Company, EA Pharma Co., Ltd., Elli Lilly and Company, Novartis AG, Merck & Co., Inc., Reistone Biophrma, and Bausch Health Companies Inc.
Some recent developments are as follows:
- On June 2022, AbbVie announced that the U.S. FDA has approved SKYRIZI, as the first and only specific Interleukin-23 (IL-23) to treat moderately to severely active Crohn’s disease for adults.
Segments Covered in the report
This report offers historical data and forecasts revenue growth at a global, regional, and country-level, and provides analysis of the market trends in each of the sub-segments from 2019 to 2030. For the purpose of this report, Reports and Data has segmented the global ulcerative colitis drug market based on drug type, route of administration, distribution channel, application, and region:
Drug Type Outlook (Revenue, USD Billion; 2019-2030)
- Biologics
- Corticosteroids
- Immunomodulators
- 5-aminosalicylic Acid
- Immunosuppressant
- Biosimilars
- Others
Route of Administration Outlook (Revenue, USD Billion; 2019-2030)
- Oral
- Injectable
Distribution Channel Outlook (Revenue, USD Billion; 2019-2030)
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Application Outlook (Revenue, USD Billion; 2019-2030)
- Proctosigmoiditis
- Ulcerative Proctitis
- Pancolitis
- Left-sided Colitis
- Acute Severe Ulcerative Colitis
Regional Outlook (Revenue, USD Billion; 2019-2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Sweden
- BENELUX
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Rest of LATAM
- Middle East & Africa
- Saudi Arabia
- UAE
- South Africa
- Israel
- Rest of MEA
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/118980/1500
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://www.visionresearchreports.com/
About Us
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/